These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35984852)

  • 21. A Tumor-Agnostic NTRK (TRK) Inhibitor.
    Huang FW; Feng FY
    Cell; 2019 Mar; 177(1):8. PubMed ID: 30901551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A
    Ann Oncol; 2019 Nov; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and Clinical Validation of a Large Fusion Gene Panel for Pediatric Cancers.
    Chang F; Lin F; Cao K; Surrey LF; Aplenc R; Bagatell R; Resnick AC; Santi M; Storm PB; Tasian SK; Waanders AJ; Hunger SP; Li MM
    J Mol Diagn; 2019 Sep; 21(5):873-883. PubMed ID: 31255796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The landscape and therapeutic relevance of cancer-associated transcript fusions.
    Yoshihara K; Wang Q; Torres-Garcia W; Zheng S; Vegesna R; Kim H; Verhaak RG
    Oncogene; 2015 Sep; 34(37):4845-54. PubMed ID: 25500544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Feasibility and clinical utility of a pan-solid tumor targeted RNA fusion panel: A single center experience.
    Hindi I; Shen G; Tan Q; Cotzia P; Snuderl M; Feng X; Jour G
    Exp Mol Pathol; 2020 Jun; 114():104403. PubMed ID: 32061944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
    Federman N; McDermott R
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
    [No Abstract]   [Full Text] [Related]  

  • 28. Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer.
    Klink AJ; Kavati A; Gassama AT; Kozlek T; Gajra A; Antoine R
    Target Oncol; 2022 May; 17(3):321-328. PubMed ID: 35716252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating Targeted Next-Generation Sequencing Assays and Reference Materials for NTRK Fusion Detection.
    Bormann Chung C; Lee J; Barritault M; Bringuier PP; Xu Z; Huang WY; Beharry A; Castillo J; Christiansen J; Lin JC; Sheffield BS
    J Mol Diagn; 2022 Jan; 24(1):18-32. PubMed ID: 34656759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NTRK testing: First results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assays.
    Kirchner M; Glade J; Lehmann U; Merkelbach-Bruse S; Hummel M; Lehmann A; Trautmann M; Kumbrink J; Jung A; Dietmaier W; Endris V; Kazdal D; Ploeger C; Evert M; Horst D; Kreipe H; Kirchner T; Wardelmann E; B├╝ttner R; Weichert W; Dietel M; Schirmacher P; Stenzinger A; Pfarr N
    Genes Chromosomes Cancer; 2020 Aug; 59(8):445-453. PubMed ID: 32319699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Multiplexed Amplicon Approach for Detecting Gene Fusions by Next-Generation Sequencing.
    Beadling C; Wald AI; Warrick A; Neff TL; Zhong S; Nikiforov YE; Corless CL; Nikiforova MN
    J Mol Diagn; 2016 Mar; 18(2):165-75. PubMed ID: 26747586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer.
    Laetsch TW; Hong DS
    Clin Cancer Res; 2021 Sep; 27(18):4974-4982. PubMed ID: 33893159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of a Next-Generation Sequencing Assay Targeting RNA for the Multiplexed Detection of Fusion Transcripts and Oncogenic Isoforms.
    Sussman RT; Oran AR; Paolillo C; Lieberman D; Morrissette JJD; Rosenbaum JN
    Arch Pathol Lab Med; 2020 Jan; 144(1):90-98. PubMed ID: 31211614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing.
    Seager M; Aisner DL; Davies KD
    J Vis Exp; 2019 Jul; (149):. PubMed ID: 31329176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.
    Nakaoku T; Tsuta K; Ichikawa H; Shiraishi K; Sakamoto H; Enari M; Furuta K; Shimada Y; Ogiwara H; Watanabe S; Nokihara H; Yasuda K; Hiramoto M; Nammo T; Ishigame T; Schetter AJ; Okayama H; Harris CC; Kim YH; Mishima M; Yokota J; Yoshida T; Kohno T
    Clin Cancer Res; 2014 Jun; 20(12):3087-93. PubMed ID: 24727320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Larotrectinib for the treatment of TRK fusion solid tumors.
    Laetsch TW; Hawkins DS
    Expert Rev Anticancer Ther; 2019 Jan; 19(1):1-10. PubMed ID: 30350734
    [No Abstract]   [Full Text] [Related]  

  • 37. Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer.
    Wong D; Yip S; Sorensen PH
    Pathol Oncol Res; 2020 Jul; 26(3):1385-1399. PubMed ID: 31256325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of Entrectinib in a Patient With the First Reported
    Sigal D; Tartar M; Xavier M; Bao F; Foley P; Luo D; Christiansen J; Hornby Z; Maneval EC; Multani P
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1317-1322. PubMed ID: 29118225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating gene fusions in solid tumors - Clinical experience using an RNA based 53 gene next-generation sequencing panel.
    Selvam P; Kelly K; Hesse AN; Spitzer D; Reddi HV
    Cancer Genet; 2019 Apr; 233-234():32-42. PubMed ID: 31109592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer.
    Xia H; Xue X; Ding H; Ou Q; Wu X; Nagasaka M; Shao YW; Hu X; Ou SI
    Clin Lung Cancer; 2020 May; 21(3):247-254. PubMed ID: 31761448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.